Abstract 127P
Background
REGN5668 (R5668) is a mucin16 (MUC16) x CD28 bispecific antibody (bsAb). R5668 provides “signal 2” T-cell costimulation through CD28 in the presence of MUC16 tumor antigen. CD28 bispecifics augment anti-tumor activity of the anti-PD-1 monoclonal Ab cemiplimab (cemi) in preclinical studies. We present the phase 1 dose-escalation results of intravenous (IV) R5668 combined with cemi in patients (pts) with recurrent platinum-experienced ovarian cancer (OC).
Methods
Pts received weekly R5668 IV at a dose range of 0.3-300 mg. Cemi 350 mg IV every 3 weeks was added beginning Day 21-28. Primary endpoints were safety and R5668 PK. Secondary endpoints included confirmed objective response rate (RECIST 1.1) and CA-125 response (Gynecologic Cancer InterGroup). Multiplex cytokine profiling was exploratory.
Results
28 pts were enrolled; 22 (79%) received ≥1 dose of cemi. Median number of prior therapies was 3.5 (range 1−10). Median duration of R5668 and cemi exposure was 7.5 (range 1.9-39.0) and 6.1 (2.4−36.0) weeks, respectively. Fatigue (32%), nausea (29%), and pain (18%) were the most common treatment-related adverse events (TRAEs). Infusion-related reactions/cytokine release syndrome (all Grade [G]1/2) occurred in 14% of pts. One pt had a G≥3 TRAE (fatigue). There were no adverse events resulting in death or study drug discontinuation. No DLTs were observed and opening of the next cohort (1000 mg) is planned. Across all pts treated to date, 1 confirmed partial response (-59% target lesion reduction from baseline) and 1 CA-125 response were observed, both in a single pt at 300 mg. 6 (21%) pts had stable disease. There was a dose-dependent increase in R5668 exposure between 1 mg and 300 mg IV QW dosing. Cytokine analyses revealed no apparent elevations after R5668 dosing, while upon cemi addition, slight increases in IFNγ and IP10 were observed.
Conclusions
In 28 heavily pretreated OC pts, an acceptable safety profile, low rates of CRS, and early activity were observed with R5668 + cemi. R5668 dose escalation with cemi or ubamatamab (MUC16xCD3 bsAb) is ongoing.
Clinical trial identification
NCT04590326.
Editorial acknowledgement
Writing assistance was provided by Brian Head, PhD, of Regeneron Pharmaceuticals, Inc.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc.
Disclosure
I.S. Winer: Financial Interests, Personal, Research Funding: Oncoceutics. R.E. O'Cearbhaill: Financial Interests, Personal, Other, Personal Fees: Bayer, Curio, Fresenius Kabi, Immunogen, MJH, Seattle Genetics and Tesaro/GSK, Miltenyi, 2seventybio; Financial Interests, Institutional, Other, Personal Fees: Regeneron; Financial Interests, Personal, Advisory Board: AbbVie/StemCentrx, Atara , Biotherapeutics, Bayer/Celgene/Juno, Genentech, Genmab/Seagen Therapeutics, Gynecologic OncologyFoundation, Kite Pharma, Ludwig Cancer Institute, Merck, Regeneron, Sellas Therapeutics, Syndax Pharmaceuticals, TCR2 Therapeutics, Lyell Therapeutics, Arsenal-Bio, Tesaro/GSK, GSK; Financial Interests, Personal, Steering Committee Member, Non-Compensated: PRIMA, Moonstone (Tesaro/GSK), and DUO-O (AstraZeneca) studies; Financial Interests, Personal, Advisory Board, Non-Compensated: Carina Biotech; Financial Interests, Personal, Other, Travel for meeting: Hitech Health. S. Bouberhan: Financial Interests, Personal, Other, Consulting Fees: ImmunoGen. J.L. Hays: Financial Interests, Personal, Advisory Role: AstraZeneca, Merck, Tesaro, Clovis Oncology, Deciphera, and Ipsen; Financial Interests, Personal, Other, Travel, accommodations, and expenses: Tesaro, Merck, and AstraZeneca. D.R. Roque: Financial Interests, Personal, Other, Honoraria: Intuitive Surgical; Financial Interests, Personal, Advisory Role: Myriad Genetics; Financial Interests, Personal, Speaker’s Bureau: GSK; Financial Interests, Personal, Other, Travel, accommodations, and expenses: Surgical. O.O. Yeku: Financial Interests, Personal, Advisory Board: TigaTx, Celldex, GIMV NV, hC Bioscience. J.F. Liu: Financial Interests, Institutional, Research Funding: Zentalis, Vigeo Therapeutics, Tesaro, Surface Oncology, Regeneron, Impact Therapeutics, GSK, CytomX Therapeutics, Clovis Oncology, Bristol Myers Squibb, AstraZeneca, Arch Oncology, Aravive, 2X Oncology; Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Daiichi, Eisai, EpsilaBio, Genentech/Roche, GSK, Regeneron Pharmaceuticals Inc., Zentalis. B. Wang, S. Yoo, S. Govindraj, M. Zhu, J. Brouwer-Visser, M.J. Peterman, B. Barnes, I. Lowy, D. Knorr, T.S. Uldrick, E.A. Miller: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display
101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study
Presenter: Ramon Yarza
Session: Poster Display
102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer
Presenter: Oladapo Yeku
Session: Poster Display
103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Presenter: Saby George
Session: Poster Display
105P - Preliminary efficacy and safety results from ‘ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.
Presenter: Yijun Shen
Session: Poster Display
106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study
Presenter: Amanda Psyrri
Session: Poster Display
108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL
Presenter: Bart Neyns
Session: Poster Display
109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy
Presenter: Inge Noringriis
Session: Poster Display
110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary
Presenter: Harpreet Wasan
Session: Poster Display